

Amendments to the Claims:

The following amendments replace all prior claims and amendments in this case.

1-11. (canceled)

12. (currently amended) An antibody which specifically binds to a polypeptide having at least 80% amino acid sequence identity to (a) a polypeptide of SEQ ID NO:44844; or (b) a polypeptide encoded by the full length coding region of the nucleotide sequence of SEQ ID NO:147 43.

13. (original) The antibody of claim 12, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.

14. (previously presented) A composition of matter comprising the antibody of Claim 12, in combination with a carrier.

15. (original) The composition of matter of claim 14, wherein said carrier is a pharmaceutically acceptable carrier.

16. (previously presented) The composition of matter of claim 14 comprising a therapeutically effective amount of the antibody of Claim 12.

17. (previously presented) An article of manufacture, comprising: a container; a label on said container; and a composition of matter comprising the antibody of Claim 12, contained within said container, wherein label on said container indicates that said composition of matter can be used for treating an immune related disease.

18-28. (canceled)